Loyal Valley Capital

company

About

Loyal Valley Capital is a thematic, research-driven private equity firm.

  • 51 - 100

Details

Industries
Asset Management,Finance,Financial Services,Venture Capital
Founded date
Jan 1, 2015
Number Of Employee
51 - 100
Operating Status
Active
Investor Type
PE

Loyal Valley Capital (LVC) is a thematic, research-driven private equity firm with strong entrepreneurial culture that invests in middle market companies positioned to benefit from the secular industry transformations in China. With over US$1.6 billion of assets under management, LVC mainly focuses on the following segments: Consumer (TMT, Internet, and Education), Healthcare, and Advanced Manufacturing. Our investment process is characterized by in-depth top-down and bottom-up fundamental research to uncover secular themes and utilize extensive industry mapping to deploy capital in a high conviction and disciplined approach. We pride ourselves as a trusted influential shareholder relentlessly focused on active value creation and accelerating growth via strategic initiatives through our extensive network of business leaders in China. LVC manages capital on behalf of international institutional investors such as sovereign wealth funds, funds of funds, private banks, and family offices, as well as elite entrepreneurs and founders of China’s Fortune 500 enterprises.

LVC was founded in 2015 by Andy Lin, an experienced investor and accomplished entrepreneur. He is the founder of China Universal Asset Management (“CUAM”), one of China’s largest equity investor and asset manager with over US$100B in AUM, known for its industry leading research and award-winning investment records.

Investments

Number of Investments
Number of Lead Investments
5
2
Loyal Valley Capital has made 5 investments. Their most recent investment was on Mar 14, 2022, when Medilink Therapeutics raised $70M.
Date Company Name
Round Money Raised Industry Lead Investor
Series B $70M Biotechnology
Series A $50M Biotechnology Yes
Apr 29, 2020 Mabwell Biotech
Series A $278.50M Biopharma
Oct 25, 2018 ByteDance
Series E $3B Content
Series C $33M Biotechnology Yes